Chronic obstructive pulmonary disease and asthma;EPOC y asma

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL. 8, 2010, Pages 2-7

  Cosío, Borja G ^a   Fiorentino, Federico ^a   Scrimini, Sergio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Atopy; Hyperreactivity; Inhaled corticosteroids; Overlap

Indexed keywords

CORTICOSTEROID; NITRIC OXIDE;

ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; EARLY DIAGNOSIS; EXPIRED AIR; HUMAN; LUNG FUNCTION; PATHOGENESIS; PHENOTYPE; PREVALENCE; PROGNOSIS;

ADRENAL CORTEX HORMONES; ADULT; AIRWAY OBSTRUCTION; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHITIS; BRONCHODILATOR AGENTS; CHILD; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RISK FACTORS; SMOKING; STATUS ASTHMATICUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952065235     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70060-0     Document Type: Article

References (50)

1. WHO. Chronic Obstructive Pulmonary Disease. Fact sheet 315. November 2009. Disponible en: 2010. http://wwwwhoint/mediacentre/factsheets/fs315/en/indexhtml.
2. WHO. Asthma. Fact sheet 307. May 2008. Disponible en: 2008. http://wwwwhoint/mediacentre/factsheets/fs307/en/indexhtml.
3. Miravitlles M., Soriano J.B., Garcia-Rio F., Munoz L., Duran-Tauleria E., Sanchez G., et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009, 64:863-868.
4. Carvajal-Uruena I., Garcia-Marcos L., Busquets-Monge R., Morales Suarez-Varela M., Garcia de Andonin N., Batlles-Garrido J., et al. Variaciones geográficas en la prevalencia de síntomas de asma en los niños y adolescentes españoles. International Study of Asthma and Allergies in Childhood (ISAAC) fase III España. Arch Bronconeumol 2005, 41:659-666.
5. Martínez-Moratalla J., Almar E., Sunyer J., Ramos J., Pereira A., Payo F., et al. Estudio Europeo del Asma. Identificación y tratamiento de individuos con criterios epidemiológicos de asma en adultos jóvenes de cinco áreas españolas. Arch Bronconeumol 1999, 35:223-228.
6. Sobradillo V., Miravitlles M., Jiménez C.A., Gabriel R., Viejo J.L., Masa J.F., et al. Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. Arch Bronconeumol 1999, 35:159-166.
7. Barnes P.J. Mechanisms in COPD: differences from asthma. Chest 2000, 117(2 Suppl):10S-40S.
8. Barnes P.J., Chung K.F., Page C.P. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998, 50:515-596.
9. 1. A longitudinal study in the elderly. Am J Respir Crit Care Med 1995, 151(3 Pt 1):656-662.
10. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8:183-192.
11. Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1773-1777.
12. Brightling C.E., Monteiro W., Ward R., Parker D., Morgan M.D., Wardlaw A.J., et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-1485.
13. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., Fitzgerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178.
14. Keatings V.M., Jatakanon A., Worsdell Y.M., Barnes P.J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155:542-548.
15. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303.
16. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999, 353:1819-1823.
17. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948-1953.
18. N Engl J Med 2000, 343:1902-1909. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.
19. Culpitt S.V., Maziak W., Loukidis S., Nightingale J.A., Matthews J.L., Barnes P.J. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1635-1639.
20. Culpitt S.V., Rogers D.F., Shah P., De Matos C., Russell R.E., Donnelly L.E., et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:24-31.
21. Barnes P.J., Ito K., Adcock I.M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004, 363:731-733.
22. Cosio B.G., Mann B., Ito K., Jazrawi E., Barnes P.J., Chung K.F., et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 2004, 170:141-147.
23. Barnes P.J. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005, 2:334-339.
24. Barnes P.J. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003, 167:813-818.
25. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., Adcock I.M., et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002, 99:8921-8926.
26. Fabbri L.M., Romagnoli M., Corbetta L., Casoni G., Busljetic K., Turato G., et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:418-424.
27. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456.
28. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
29. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81.
30. Thomson N.C., Shepherd M., Spears M., Chaudhuri R. Corticosteroid insensitivity in smokers with asthma: clinical evidence, mechanisms, and management. Treat Respir Med 2006, 5:467-481.
31. Am J Respir Crit Care Med 1995, 152(5 Pt 2):S77-S121. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
32. Soriano J.B., Davis K.J., Coleman B., Visick G., Mannino D., Pride N.B. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003, 124:474-481.
33. Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 2009, 64:728-735.
34. Weatherall M., Travers J., Shirtcliffe P.M., Marsh S.E., Williams M.V., Nowitz M.R., et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009, 34:812-818.
35. Orie N.G., Slutter H.J., De Vrie K., Tammeling G.J. Chronic nonspecific respiratory diseases. Ned Tijdschr Geneeskd 1961, 105:2136-2139.
36. Kanner R.E., Connett J.E., Altose M.D., Buist A.S., Lee W.W., Tashkin D.P., et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med 1994, 150:956-961.
37. Wise R.A., Kanner R.E., Lindgren P., Connett J.E., Altose M.D., Enright P.L., et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest 2003, 124:449-458.
38. Brutsche M.H., Downs S.H., Schindler C., Gerbase M.W., Schwartz J., Frey M., et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006, 61:671-677.
39. Hospers J.J., Postma D.S., Rijcken B., Weiss S.T., Schouten J.P. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000, 356:1313-1317.
40. Peces-Barba G., Barbera J.A., Agusti A., Casanova C., Casas A., Izquierdo J.L., et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281.
41. Wedzicha J.A., Calverley P.M., Seemungal T.A., Hagan G., Ansari Z., Stockley R.A. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26.
42. Singh S., Amin A.V., Loke Y.K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009, 169:219-229.
43. Suissa S., McGhan R., Niewoehner D., Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007, 4:535-542.
44. Brightling C.E., McKenna S., Hargadon B., Birring S., Green R., Siva R., et al. Sputum eosino philia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005, 60:193-198.
45. Leigh R., Pizzichini M.M., Morris M.M., Maltais F., Hargreave F.E., Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006, 27:964-971.
46. Smith D.F., Toft D.O. Steroid receptors and their associated proteins. Mol Endocrinol 1993, 7:4-11.
47. Dummer J.F., Epton M.J., Cowan J.O., Cook J.M., Condliffe R., Landhuis C.E., et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med 2009, 180:846-852.
48. Lehtimaki L., Kankaanranta H., Saarelainen S., Annila I., Aine T., Nieminen R., et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur Respir J 2010, 35:72-78.
49. Sont J.K., Willems L.N., Bel E.H., Van Krieken J.H., Vandenbroucke J.P., Sterk P.J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999, 159(4 Pt 1):1043-1051.
50. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.